Project UpdateJul 7, 2026, 04:07 PM
Clearmind Reports Successful MEAI Intranasal Formulation Study
AI Summary
Clearmind Medicine Inc. announced the successful completion of a formulation feasibility study for intranasal delivery of its proprietary MEAI (5-Methoxy-2-aminoindane). This development supports a potential new additional route of administration for MEAI, initially targeting alcohol use disorder (AUD). The study confirmed MEAI's compatibility and suitability for intranasal administration, resulting in a stable and fully soluble solution, which the company believes will enhance therapeutic potential and patient experience.
Key Highlights
- Clearmind reported a successful formulation feasibility study for intranasal MEAI.
- The study supports the potential development of a new additional route of administration for MEAI.
- Initial focus for intranasal MEAI is on the treatment of alcohol use disorder (AUD).
- The program aims to combine a novel therapeutic molecule with an advanced drug delivery platform.
- MEAI demonstrated compatibility and suitability for intranasal administration in the study.
- The formulation resulted in a stable and fully soluble solution, providing a strong foundation for further development.
Price Impact
More from CMND